NCT04425187

Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC

Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC Clinical Study of L858R Positive Mutation Patients

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Fudan University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To compare the efficacy and safety of gefitinib combined with bevacizumab and gefitinib in the treatment of L858R positive mutation in exon 21 of EGFR gene in advanced NSCLC.

Conditions

• PFS

Interventions

Type	Name	Description
DRUG	Gefitinib	gefitinib 250mg (1 tablet), once a day，PO
DRUG	Bevacizumab Combined With Gefitinib	Bevacizumab Combined With Gefitinib

Timeline

• Start date: 2020-06-08
• Primary completion: 2021-12-31
• Completion: 2022-12-31
• First posted: 2020-06-11
• Last updated: 2020-06-12

Locations

1 site across 1 country: China